Wikipedia -WSS

Wikipedia

author：focus 2025-09-30 00:48:23 - browse：95

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

LONDON — A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, its developers said Monday, as the competition in the broader obesity medicine field pushes ahead.

The drug, survodutide, is being developed by the privately held German firm Boehringer Ingelheim and the Danish biotech Zealand Pharma. Zealand’s share price has doubled over the past year over the potential of the drug, and on Monday morning, shares jumped another 25%.

In the study, 83% of patients with a condition called MASH and who were treated with survodutide saw significant improvements in their disease compared to 18% of those who received placebo. The study met its primary endpoint of improvements in MASH after 48 weeks without the worsening of fibrosis, a scarring of the liver, the companies said. Secondary endpoints were also met, including an improvement in fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

entertainment

knowledge

WSS

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

FDA panel signals lack of confidence in Amgen cancer drug data

FDA panel signals lack of confidence in Amgen cancer drug data

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

WuXi Biologics execs register to lobby as Congress comes for the company

FDA rejects Alnylam's heart disease treatment over insufficient data

hotspot

Wikipedia

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

In Memoriam: Notable people who died in 2023

Was Amgen transparent enough on FDA's concern on cancer drug?

Medicare details structure of new drug price negotiation program

FDA rejects Alnylam's heart disease treatment over insufficient data

Medical records are filled with copy

STAT series 'Denied by AI' wins major journalism prizes

At least 13 dead in Texas as scorching temps continue

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

focus

Colorectal cancer study finds potential in overlooked immune cell

WuXi Biologics beefs up its lobbying operation

HHS suspends federal funding for EcoHealth Alliance

Obesity drug from Roche shows promise in early study

When women are denied an abortion, their children fare worse than peers

CVS is willing to dump 10% of its Medicare Advantage members

leisure time

entertainment

knowledge

focus